Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
Conditions
Keywords
Pancreatic Cancer, Palliative Chemotherapy
Brief summary
The study objectives are to find out: 1) palliative chemotherapy patterns and prognosis in patients with locally advanced or metastatic pancreatic cancer in Korea's real clinical settings, and 2) reasons adopted by clinicians in choosing therapeutic drugs.
Detailed description
This study is a domestic, multi-center, prospective, observational study designed for locally advanced or metastatic pancreatic cancer patients who plan to receive palliative chemotherapy. When patients voluntarily express their consent to provide their information to this study by signing a written agreement, their baseline information including demographics, comorbidities, pancreatic cancer-related information, medical treatment history, etc. shall be used for screening. When patients are judged eligible for study participation, they shall receive an appropriate palliative chemotherapy. After first-line chemotherapy (baseline), information review shall be conducted at month 2, 6 and 12 for chemotherapy currently in use (whether or not chemotherapy ended/discontinued and relevant reasons; type, frequency and duration of administered drugs), RECIST, quality of life (month 2 and 6), activity performance assessment, laboratory tests, tumor marker test, adverse drug reactions, etc. However, if first-line chemotherapy moves to second-line chemotherapy due to causes such as progressive disease (PD), information review shall be restricted to the relevant drug name and survival until the end of the study (month 12).
Interventions
None listed
Sponsors
Boryung Pharmaceutical Co., Ltd
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients are briefed about the study objectives and methodologies, and express their consent by signing a written agreement for the use of their personal information. 2. Male and female adults who are ≥ 19 years old at the time of enrollment. 3. Locally advanced or metastatic pancreatic cancer patients whose diagnosis was confirmed histologically or cytologically. 4. Patients who plan to receive palliative chemotherapy (e.g., FOLFIRINOX, Gemcitabine-based therapy, etc.)
Exclusion criteria
1. Patients who are diagnosed with any other primary cancer that may influence pancreatic cancer treatment or prognosis. 2. Patients who are currently or have a history of receiving palliative chemotherapy. 3. Female patients who are pregnant, have childbearing potential or are breastfeeding. 4. Patients who are currently participating in other clinical trials (clinical trials for drugs or medical devices) or are planning to participate in other clinical trials during the study period. However, patients participating in a non-interventional observational study or registry study can be enrolled. 5. Other patients who are judged by the investigator to be ineligible to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | From date of the first tumor response until the date of first documented progression, assessed up to 12 months | Progression-free survival (PFS) by first-line palliative chemotherapy |
| Chemotherapy patterns(Type of the second-line palliative chemotherapy) | up to 12 months | Type of the second-line palliative chemotherapy for each first-line palliative chemotherapy |
| Overall Survival (OS) | From date of enrollment until the date of death, assessed up to 12 months | Overall Survival (OS) by first-line palliative chemotherapy |
| Chemotherapy patterns(Type of the first-line palliative chemotherapy) | Baseline | Type of the first-line palliative chemotherapy and reasons for therapy selection/discontinuation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life Assessment | Baseline, Month 2, Month 6 | Quality of life (FACT-Hep) changes in month 2 and 6 after palliative chemotherapy compared to previous therapy |
| Total administration period | through the first-line chemotheraphy completion, assessed up to 12 months | Total administration period of the first palliative chemotherapy. |
| The best response | through the first-line chemotheraphy completion, assessed up to 12 months | The best response according to RECIST 1.1 criteria, objective response rate (ORR) and disease control rate (DCR) |
| Eastern Cooperative Oncology Group Performance Status (ECOG PS) scores | Baseline, Month 2, Month 6, Month 12 | Changes in ECOG PS scores at month 2, 6 and 12 after palliative chemotherapy compared to previous therapy. The minimum value is 0 and the maximum value is 5, and higher scores mean a worse outcome. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Adverse drug reactions(ADR) | From the date of the first-line chemotheraphy started until the end of follow-up(12 months) | Incidence of adverse drug reactions (ADR) associated with first-line palliative chemotherapy |
| Adverse drug reactions(ADR) caused delay/discontinuation of planned chemotherapy | From the date of the first-line chemotheraphy started until the end of follow-up(12 months) | Incidence of ADRs that caused delay/discontinuation of planned chemotherapy |
| Serious adverse drug reactions(SADR) | From the date of the first-line chemotheraphy started until the end of follow-up(12 months) | Incidence of serious adverse drug reactions (SADR) associated with first-line palliative chemotherapy |
Countries
South Korea
Outcome results
None listed